%0 Journal Article
%A Encinas, Cristina
%A Hernandez-Rivas, José-Ángel
%A Oriol, Albert
%A Rosiñol, Laura
%A Blanchard, María-Jesús
%A Bellón, José-María
%A García-Sanz, Ramón
%A de la Rubia, Javier
%A de la Guía, Ana López
%A Jímenez-Ubieto, Ana
%A Jarque, Isidro
%A Iñigo, Belén
%A Dourdil, Victoria
%A de Arriba, Felipe
%A Pérez-Ávila, Clara Cuéllar
%A Gonzalez, Yolanda
%A Hernández, Miguel-Teodoro
%A Bargay, Joan
%A Granell, Miguel
%A Rodríguez-Otero, Paula
%A Silvent, Maialen
%A Cabrera, Carmen
%A Rios, Rafael
%A Alegre, Adrián
%A Gironella, Mercedes
%A Gonzalez, Marta-Sonia
%A Sureda, Anna
%A Sampol, Antonia
%A Ocio, Enrique M
%A Krsnik, Isabel
%A García, Antonio
%A García-Mateo, Aránzazu
%A Soler, Joan-Alfons
%A Martín, Jesús
%A Arguiñano, José-María
%A Mateos, María-Victoria
%A Bladé, Joan
%A San-Miguel, Jesús F
%A Lahuerta, Juan-José
%A Martínez-López, Joaquín
%A GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group
%T A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma.
%D 2022
%U http://hdl.handle.net/10668/19516
%X Infections remain a common complication in patients with multiple myeloma (MM) and are associated with morbidity and mortality. A risk score to predict the probability of early severe infection could help to identify the patients that would benefit from preventive measures. We undertook a post hoc analysis of infections in four clinical trials from the Spanish Myeloma Group, involving a total of 1347 patients (847 transplant candidates). Regarding the GEM2010 > 65 trial, antibiotic prophylaxis was mandatory, so we excluded it from the final analysis. The incidence of severe infection episodes within the first 6 months was 13.8%, and majority of the patients experiencing the first episode before 4 months (11.1%). 1.2% of patients died because of infections within the first 6 months (1% before 4 months). Variables associated with increased risk of severe infection in the first 4 months included serum albumin ≤30 g/L, ECOG > 1, male sex, and non-IgA type MM. A simple risk score with these variables facilitated the identification of three risk groups with different probabilities of severe infection within the first 4 months: low-risk (score 0-2) 8.2%; intermediate-risk (score 3) 19.2%; and high-risk (score 4) 28.3%. Patients with intermediate/high risk could be candidates for prophylactic antibiotic therapies.
%~